Item 8.01. Other Events.

On January 4, 2021, Zosano Pharma Corporation issued a press release announcing that it has submitted a Type A meeting request to the U.S. Food and Drug Administration ("FDA") to discuss the complete response letter received from the FDA in connection with the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.



                                        Description

 99.1      Press Release dated January 4, 2021 titled "Zosano Pharma Requests Type
         A Meeting with the FDA to Review Resubmission Plans for Qtrypta™ New Drug
         Application"

104.1    Cover Page Interactive Data File (embedded within the Inline XBRL
         document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses